If you buy exam gloves, wound dressings or any other single-use medical consumables for a hospital, a care home or a distributor, the cost line in your supplier quote has probably moved this year. And the move was not caused by a shortage. It was caused by two separate pressures landing on the same product at the same time: a raw-material shock upstream and a tariff wall downstream.
The raw-material shock: nitrile latex roughly doubled
The base material behind nitrile gloves is nitrile latex, and its price moved sharply in early 2026. According to Top Glove, nitrile latex rose from roughly USD 750 per tonne to approximately USD 1,500 per tonne - effectively a doubling of the core input for the single most widely used examination glove in the world.
Convert that into finished-goods terms and the picture becomes concrete. Industry reporting in 2026 puts the resulting increase in nitrile glove costs at around 31.1% year on year. Wholesale pricing reflects it: standard exam-grade nitrile gloves are quoted in a range of roughly USD 80 to USD 140 per case of 1,000 units in 2026, with higher-grade and specialised products reaching USD 120 to USD 275 and above per case.
For a buyer, the important detail is that this is not a glove shortage story. Gloves are abundant; the material they are made from is not free any more. That distinction matters because it changes where the negotiation leverage sits.
The tariff wall: Section 301 duties that were scheduled to bite in 2026
On the trade-policy side, the cost picture has a second, independent layer. The Section 301 review raised duty rates on several Chinese medical product lines, with medical gloves, syringes, needles and related protective items appearing in the scope of those increases, and the 2026 tranche of those increases taking effect from January 1, 2026.
Chinese-origin goods also continue to carry the earlier China Section 301 duties on top of any newer measures - a cumulative burden that can reach very high single-digit to triple-digit percentage rates on the most heavily targeted lines such as syringes, needles and rubber medical gloves. Duty is assessed on the value entering the destination market, so it compounds with every other cost increase in the same shipment rather than replacing it.
Put the two together and a glove that was quoted at X can arrive at X multiplied by three independent factors: input cost, duty rate, and freight. None of them is negotiable at the purchasing stage. All of them were decided upstream.
What the demand side is doing while prices rise
It would be a mistake to read this purely as a cost story. The underlying demand for single-use consumables continues to expand, which is part of why upstream suppliers can pass cost through instead of absorbing it.
- The global medical gloves market is projected to grow from roughly USD 15.95 billion in 2026 to about USD 38.54 billion by 2035, a compound annual growth rate of approximately 10.3%.
- Incontinence and ostomy care products are forecast to expand from around USD 20.5 billion in 2026 to approximately USD 29.3 billion by 2033, a CAGR of about 5.2%.
- Incontinence care products overall were valued near USD 13.99 billion in 2025 and are estimated to reach around USD 20.85 billion by 2032, with a CAGR of roughly 7.1%.
- Reusable adult diapers are expected to account for about 41.6% of global revenue in 2025, supported by cost efficiency and sustainability.
The structural driver is demographic and institutional at once: ageing populations combined with the continued shift of care from hospital beds into the home. Home-care settings are consumable-intensive by nature, and the products used there - incontinence care, wipes, dressings, protective pads - sit directly in the path of this cost increase.
Five moves that actually reduce the landed cost
Buyers who respond to a cost increase with a price negotiation alone are negotiating against a rising tide. The levers that work are structural, and most of them are decided at qualification time rather than at order time:
- Audit the landed cost, not the ex-works price. Duty is assessed on the value entering the destination market. A modest FOB increase can be offset by a change in how value is documented and valued, within the rules. Build the duty line into your cost model explicitly rather than treating it as a surprise at clearance.
- Tier your product range. Premium and high-grade glove lines carry a much wider price spread than standard exam grade. In a cost-pressured year, standard grade for routine clinical use and premium grade only where the clinical case genuinely requires it is a defensible specification strategy.
- Diversify the manufacturing base. A single-country manufacturing dependency exposes you to that country's trade-policy calendar. Having qualified production across multiple countries is expensive to build and cheap to have.
- Lock specification and re-bid on volume, not on price. A specification change is a re-qualification event with real cost. Keeping the technical specification stable and negotiating on volume, packaging format and delivery terms avoids paying twice - once in requalification, once in unit price.
- Use dual-sourced approval even for a single category. A qualified alternate supplier is worth more than a price discount. It is the only protection that does not depend on market conditions staying favourable.
The structural read
What is happening now is not a temporary disruption. Raw-material repricing and tariff schedules are both slow-moving, policy-driven variables, and both are now trending in the same direction for the same product categories. The predictable consequence is that glove and consumable prices in the export market will hold at a structurally higher level through the rest of this decade, with periodic spikes whenever a new tariff tranche or a raw-material move lands.
For manufacturers and exporters, the strategic response is qualification capacity rather than negotiating stamina: more capacity, more approved lines, more countries of manufacture, and faster response when a buyer needs a change tomorrow. For buyers, the response is a supplier base that can absorb a shock without forcing a stock-out on a ward or a care home.
At Wehere Medical we have spent more than 25 years in disposable medical consumables manufacturing and export, working to ISO 13485 and EU MDR requirements across three owned factories and 45 audited partner factories, covering more than 2,500 product lines supplied into over 50 countries. In a year when input costs and duties are moving together, what matters to our customers is not the lowest quoted price but predictable landed cost and a 24-hour response when something has to change.
Sources
- Top Glove, nitrile latex pricing commentary on 2026 input cost movement (reported via CenterPoint Group, 2026)
- CenterPoint Group, "Why nitrile glove costs rose 31.1% in 2026"
- USTR Section 301 tariff modifications and effective dates for the 2026 tranche (reported 2026)
- Market Research Future, Medical Gloves Market (2026-2035 outlook)
- Persistence Market Research, Incontinence and Ostomy Care Products Market (2026-2033 outlook)
- Verified Market Reports, Incontinence Care Products Market (2025-2032 outlook)
